HomeContact

Quark Biotech Inc


Drug discovery and development, genomics research


Quark is an evolving pharmaceutical company, based in Fermont, USA, using rational drug design for the development of new therapeutics for unmet medical needs.


Daniel Zurr, Ph.D., CEO
Rami Skaliter, Ph.D. COO
Shai Erlich, Ph.D., Chief Development Officer
Elena Feinstein, Ph.D., CSO


Philip B. Simon, Chairman
Joseph Rubinfeld, Ph.D., Vice Chairman
Steven B. Fink
Daniel Zurr, PhD
Tomomi Okamoto


Bruce Molitoris, MD
Patrick Murray, MD
Emil Paganini, MD
Lakhmir Chawla, MD
Ravindra L. Mehta, MD
Dganit Dinour, MD
Jayakrishna Ambati MD
Jason Slakter, MD
Philip J. Rosenfeld, MD, PhD
Ayala Pollack, MD
Anat Loewenstein, MD
Dov Weinberger, MD
Peter K. Kaiser, MD


6501 Dumbarton Circle
Fremont, CA 94555
USA
Phone: +1-510-402-4020
Fax: +1-510-402-4021


The company’s proprietary technology for gene discovery, BiFAR, is used to identify and target genes involved in serious diseases. The drugs under development belong to the class of siRNA drugs (RNA interference mechanism). The company’s drug pipeline also includes small molecule and antibody drug candidates.


Two siRNA drugs are ending phase I/IIa and entering full phase II sometime in 2007 - one for the treatment of age-related macular degeneration and one for the prevention of acute renal failure.

The following section contains a selection of the company’s most relevant patents. For comprehensive patent information please refer to the espacenet databases.

Related patents